Table 6 Case report of dupilumab for the management of ICEP
From: Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review
Doses | Number of participants | Duration of follow-up after biological | Age/sex/Comorbidities | Outcomes | Case report reference | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Respiratory symptoms | Relapses | Systemic corticosteroid | Radiological findings | Lung function | Quality of life | Adverse events | |||||
Dupilumab 300Â mg every 2 weeks for 6 months | 1 | 12 months | Female, 11 years old. No response to antibiotic management, systemic steroids, or cyclosporine | Improvement at 2 weeks | None after start | Tolerated withdrawal and decrease in cyclosporine | Improvement at 2 weeks | Not described | Not described | No adverse events during handling | Fowler 2020 [55]. |